Edition:
United Kingdom

T2 Biosystems Inc (TTOO.OQ)

TTOO.OQ on NASDAQ Stock Exchange Global Market

4.06USD
13 Dec 2017
Change (% chg)

$0.06 (+1.50%)
Prev Close
$4.00
Open
$4.03
Day's High
$4.11
Day's Low
$3.96
Volume
45,218
Avg. Vol
58,752
52-wk High
$6.97
52-wk Low
$2.51

Summary

Name Age Since Current Position

John McDonough

57 2007 President, Chief Executive Officer, Director

Michael Cima

57 2006 Co-Founder, Independent Director

Darlene Deptula-Hicks

59 2017 Chief Financial Officer, Senior Vice President, Treasurer

Joanne Spadoro

58 2016 Chief Operations Officer

Rahul Dhanda

44 2016 Senior Vice President - Corporate Development

Thomas Lowery

38 2013 Chief Scientific Officer

Michael Gibbs

46 2016 Vice President, General Counsel

Michael Pfaller

66 2014 Chief Medical Officer

Seymour Liebman

68 2016 Director

John Cumming

71 2014 Independent Director

David Elsbree

69 2014 Independent Director

Adrian Jones

62 2016 Independent Director

Stan Lapidus

67 2008 Independent Director

Biographies

Name Description

John McDonough

Mr. John McDonough is the President, Chief Executive Officer, Director T2 Biosystems, Inc. He has served as our President and Chief Executive Officer and a member of our Board of Directors since November 2007. From 2003 to 2007, Mr. McDonough held various positions at Cytyc Corporation, a company engaged in the design, development, manufacturing and marketing of clinical products that focus on women's health, where he ultimately served as President of Cytyc Development Corporation. Mr. McDonough received his B.S.B.A. from Stonehill College. Mr. McDonough's extensive management experience as a senior executive and his diagnostic company experience contributed to our Board of Directors' conclusion that he should serve as a director of our company.

Michael Cima

Dr. Michael J. Cima, Ph.D., is a Co-Founder, Independent Director at T2 Biosystems, Inc. Since 1986, Dr. Cima has been a Professor of Materials Science and Engineering at Massachusetts Institute of Technology, or MIT, and he currently holds the David H. Koch Engineering Chair and an appointment at the Koch Institute for Integrative Cancer Research. Dr. Cima received his B.S. in chemistry and his Ph.D. in chemical engineering, both from the University of California at Berkeley. Dr. Cima's extensive life science experience and knowledge of the diagnostics industry contributed to our Board of Directors' conclusion that he should serve as a director of our company.

Darlene Deptula-Hicks

Ms. Darlene Deptula-Hicks is Chief Financial Officer, Senior Vice President, Treasurer of the Company. Ms. Deptula-Hicks was the Acting Chief Financial Officer for Pieris Pharmaceuticals, Inc., a clinical stage biotechnology company, from November 2014 to August 2015, and Senior Vice President & Chief Financial Officer from September 2015 to February 2017. From October 2014 to September 2015, Ms. Deptula-Hicks was also the Acting Chief Financial Officer for Claritas Genomics Inc., a clinical pediatric genetic testing company. From June 2012 to October 2014, Ms. Deptula-Hicks was Executive Vice President and Chief Financial Officer for Microline Surgical, Inc., a manufacturer of minimally invasive reposable surgical instruments and advanced electro-surgical devices. From 2006 to 2011, Ms. Deptula-Hicks was Executive Vice President and Chief Financial Officer at ICAD, Inc., a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification, treatment and monitoring of certain cancers. Ms. Deptula-Hicks received her M.B.A. from Rivier College and her B.S. in accounting from Southern New Hampshire University.

Joanne Spadoro

Dr. Joanne Spadoro, Ph.D. has been appointed as Chief Operations Officer of the Company. From 2010 until she joined our company, Dr. Spadoro held various senior positions at Immucor, including Chief Scientific Officer and Vice President of Worldwide Operations. From 2000 to 2009, Dr. Spadoro held various positions at Roche Molecular Systems, including Senior Vice President heading global development and operations functions. Dr. Spadoro received her Ph.D. in cell biology from the University of Connecticut and her B.A. in biological sciences from Douglass College.

Rahul Dhanda

Mr. Rahul K. Dhanda is Senior Vice President - Corporate Development of T2 Biosystems, Inc. Since joining our company in 2008, Mr. Dhanda has held several leadership roles, including Vice President of Marketing since 2010. From June 2005 until he joined our company, Mr. Dhanda worked in marketing at Boston Scientific’s Urology division, where he led the team responsible for the Access, Visualization and Laser Lithotripsy franchises. From May 2001 to June 2004, Mr. Dhanda worked in business development at Interleukin Genetics. Mr. Dhanda is a former committee member of the AAAS Committee on Scientific Freedom and Responsibility. Mr. Dhanda received his M.B.A. from MIT’s Sloan School of Management and his B.A. in History from Wesleyan University.

Thomas Lowery

Dr. Thomas J. Lowery Ph.D. is Chief Scientific Officer ofT2 Biosystems. He has served as our Chief Scientific Officer since September 2013. Since joining our company in 2007, Dr. Lowery has held various technical leadership roles in the assay, methods, reagents and detector development programs. Prior to joining our company, Dr. Lowery conducted research at the University of California Berkeley focused on developing innovative magnetic resonance based biosensors for molecular imaging. Dr. Lowery received his Ph.D. in chemistry from the University of California, Berkeley and his B.S. in biochemistry from Brigham Young University.

Michael Gibbs

Mr. Michael Gibbs is Vice President, General Counsel of the Company. Mr. Gibbs joined our company in December 2014 as Senior Corporate Counsel. From 2011 until he joined our company, Mr. Gibbs was General Counsel for Keystone Dental, Inc., a medical device company. From 2003 to 2011, Mr. Gibbs was a corporate attorney with the law firm Bingham McCutchen LLP (now Morgan Lewis & Bockius). Prior to joining Bingham McCutchen LLP, he was an officer in the United States Marine Corps, departing with the rank of Major. Mr. Gibbs received his J.D. from Boston College Law School and his B.S. in Political Science from Syracuse University.

Michael Pfaller

Mr. Michael A. Pfaller, M.D. is a Chief Medical Officer of T2 Biosystems inc., since March 2014. He has served as our Chief Medical Officer since March 2014. From 2005 until he joined our company, Dr. Pfaller was a consultant to JMI Laboratories, managing the in vitro testing of fungal and bacterial isolates. From 1983 to 2005, he was Clinical Director of Clinical Microbiology Laboratory at the University of Iowa, as well as Interim Director of Clinical Laboratories from 1984 to 1985. He currently serves as Co-Editor in Chief of the American Society for Microbiology Manual of Clinical Microbiology, 11 th edition and as co-editor of the 8 th edition of Medical Microbiology. Dr. Pfaller received his M.D. from the Washington University School of Medicine and his B.A. in chemistry from Linfield College.

Seymour Liebman

Mr. Seymour E. Liebman serves as Director of the Company. Mr. Liebman has been employed by Canon USA, Inc. since 1974 and currently serves as its Executive Vice President, Chief Administrative Officer and General Counsel, Senior Managing Executive Officer of Canon Inc., Japan, and Vice Chairman, Canon Solutions America, Inc. Mr. Liebman received his J.D. from Touro Law School, his M.S. in mathematics from Rutgers University, his M.S. in accounting from Long Island University and his B.A. in mathematics from Hofstra University. Mr. Liebman’s management and board experience contributed to our Board of Directors' conclusion that he should serve as a director of our company.

John Cumming

Mr. John W. Cumming is an Independent Director of the Company. Mr. Cumming currently serves as Chief Executive Officer and Managing Director of Cumming & Associates LLC, a strategic advisory firm serving the healthcare industry. From August 2000 until December 2013, Mr. Cumming served in a number of leadership roles at Hologic Inc., a diagnostics company, including as Chief Executive Officer from 2001 through 2009 and again from July 2013 through December 2013, as President from 2001 until 2003, as Chairman of the Board from 2002 until 2007 and again from 2008 through 2011, and as Global Strategic Advisor from 2011 through July 2013. Mr. Cumming attended the University of South Carolina. Mr. Cumming's extensive knowledge of and experience with diagnostic product companies and expertise as a strategic advisor focused on the healthcare industry contributed to our Board of Directors' conclusion that he should serve as a director of our company.

David Elsbree

Mr. David B. Elsbree is an Independent Director of T2 Biosystems., since July 2014. From 1970 until 2004, Mr. Elsbree was employed by Deloitte & Touche, most recently as a senior partner. Mr. Elsbree served in a number of leadership roles in the firm's high technology practice, including partner-in-charge of the New England High Technology Practice. Mr. Elsbree served on the board of directors of Art Technology Group, Inc. from June 2004 until January 2011 and on the board of directors of Acme Packet, Inc. from November 2006 until March 2013. Mr. Elsbree received his B.A. from Northeastern University. Mr. Elsbree's extensive knowledge of and experience with technology companies and financial expertise contributed to our Board of Directors' conclusion that he should serve as a director of our company.

Adrian Jones

Mr. Adrian M. Jones is Independent Director of the Company. Since 1994, Mr. Jones has been employed by Goldman, Sachs & Co., currently serving as a managing director, co-head of the Americas Equity business and a member of the Global Investment Committee. From 1983 to 1989, Mr. Jones served as a lieutenant in the Irish Army, including two years in the United Nations Peacekeeping Force in Southern Lebanon. In the last five years, Mr. Jones has represented GS Capital Partners on the board of directors of Education Management Corp. from 2006 to 2015 and Dollar General Corp. from 2007 to 2013. In addition, Mr. Jones serves on the boards of Autism Speaks, The American Ireland Fund and the Galway University Foundation. Mr. Jones received his M.B.A. from Harvard Business School, his M.A. in Economics from University College, Dublin and his B.A. in Economics and Politics from University College, Galway. Mr. Jones’ management experience, including his extensive experience in business strategy for healthcare companies, contributed to our Board of Directors' conclusion that he should serve as a director of our company.

Stan Lapidus

Mr. Stanley N. Lapidus is an Independent Director of T2 Biosystems, Inc. Mr. Lapidus is President and Chief Executive Officer of SynapDx, an autism early detection company he founded in 2009. From 2003 to 2008, Mr. Lapidus was Chief Executive Officer of Helicos Biosciences, a life science company he co-founded in 2003. From 1995 to 2001, he was Chief Executive Officer of EXACT Sciences, a colorectal cancer diagnostics company he founded in 1995. From 1987 to 1994, he was Chief Executive Officer of Cytyc Corp., a cervical cancer diagnostics company he founded in 1987. Mr. Lapidus holds an academic appointment at MIT. He received his B.S. in engineering from Cooper Union. Mr. Lapidus' experience as a senior executive and his knowledge of life science companies contributed to our Board of Directors' conclusion that he should serve as a director of our company.

Basic Compensation